Abstract
(-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Current Neuropharmacology
Title: The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Volume: 5 Issue: 4
Author(s): Kechun Yang, Guozhang Jin and Jie Wu
Affiliation:
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Abstract: (-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Export Options
About this article
Cite this article as:
Yang Kechun, Jin Guozhang and Wu Jie, The Neuropharmacology of (-)-Stepholidine and its Potential Applications, Current Neuropharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157015907782793649
DOI https://dx.doi.org/10.2174/157015907782793649 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Mobile Phone Text Message Interventions in Psychiatry - What are the Possibilities?
Current Psychiatry Reviews Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects
Current Drug Safety L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Glutamate Receptors as Therapeutic Targets for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats
Current Molecular Pharmacology Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimers Disease
Current Alzheimer Research Restoration of the Striatal Dopamine Synthesis for Parkinsons Disease:Viral Vector-Mediated Enzyme Replacement Strategy
Current Gene Therapy Antipsychotic Polypharmacy
Current Pharmaceutical Design Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry